The Rumors Were True: Abbott Buys St. Jude For $25b To Create Third Cardiovascular Giant
This article was originally published in Clinica
Executive Summary
Abbott Laboratories has agreed to acquire St. Jude Medical for $25bn, creating a third player, along with Boston Scientific and Medtronic, that competes in all major sectors of the cardiovascular device business.
You may also be interested in...
Abbott Unit Aims To Settle Investor Suit
Thoratec has agreed with plaintiffs to pay $12m to settle a lawsuit alleging the company hid negative information about the company’s heart pump, thus keeping share prices artificially high. A hearing is scheduled on the settlement for next month.
BD, CR Bard Merger To Create Vascular Access Device Giant
Becton Dickinson has reached a definitive agreement to acquire CR Bard for $24bn. BD says Bard's product portfolio gives it a strong presence in fast-growing clinical areas and more reach outside the US while Bard expects to reach more customers by building on BD's leadership in medication management and infection prevention.
Medtechs At The Wheel In New Health Care Landscape
2016 was a year of surprise and change in political circles, but that's nothing new for the medtech industry, which over a number of years has become accustomed to health care systems demanding different and ever-higher levels of service. Smart medtechs have been ahead of the curve, but the whole industry now factors in clients' wider needs in a holistic approach to patient care. Many companies' current M&A policies are already reflecting the changes to come.